Use of antimalarial drugs in the treatment of COVID-19: A window of opportunity?
作者信息
Lasheras Isabel, Santabárbara Javier
机构信息
Departamento de Microbiología, Medicina Preventiva y Salud Pública, Universidad de Zaragoza, Zaragoza, España.
Departamento de Microbiología, Medicina Preventiva y Salud Pública, Universidad de Zaragoza, Zaragoza, España; Instituto de Investigación Sanitaria de Aragón (IIS Aragón), Zaragoza, España; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Ministerio de Ciencia e Innovación, Madrid, España.
出版信息
Med Clin (Barc). 2020 Jul 10;155(1):23-25. doi: 10.1016/j.medcli.2020.04.004. Epub 2020 Apr 22.
Abstract
摘要
相似文献
1
Use of antimalarial drugs in the treatment of COVID-19: A window of opportunity?
Med Clin (Barc). 2020 Jul 10;155(1):23-25. doi: 10.1016/j.medcli.2020.04.004. Epub 2020 Apr 22.
2
COVID-19 and Antimalarial Drugs: Harms Outweigh Benefits.
Am J Crit Care. 2020 Nov 1;29(6):489-492. doi: 10.4037/ajcc2020694.
3
Ventricular arrhythmia risk due to chloroquine / hydroxychloroquine treatment for COVID-19: Should it be given.
Indian Heart J. 2020 Mar-Apr;72(2):131-132. doi: 10.1016/j.ihj.2020.04.006. Epub 2020 Apr 27.
4
Effects of disruption from COVID-19 on antimalarial strategies.
Nat Med. 2020 Sep;26(9):1334-1336. doi: 10.1038/s41591-020-1047-5.
5
Regulators split on antimalarials for COVID-19.
Lancet. 2020 Apr 11;395(10231):1179. doi: 10.1016/S0140-6736(20)30817-5.
6
Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?
Indian J Public Health. 2020 Jun;64(Supplement):S125-S127. doi: 10.4103/ijph.IJPH_496_20.
7
Acute meningoencephalitis in a patient with COVID-19.
Rev Neurol (Paris). 2020 Jun;176(6):519-521. doi: 10.1016/j.neurol.2020.04.014. Epub 2020 May 11.
8
The Effect of Anticoagulation Use on Mortality in COVID-19 Infection.
Am J Cardiol. 2020 Nov 1;134:155-157. doi: 10.1016/j.amjcard.2020.08.005. Epub 2020 Aug 15.
9
COVID-19 will further exacerbate global antimicrobial resistance.
J Travel Med. 2020 Sep 26;27(6). doi: 10.1093/jtm/taaa098.
10
Therapeutic conflict in patients with COVID-19 and glaucoma.
Med Clin (Barc). 2020 Aug 28;155(4):182. doi: 10.1016/j.medcli.2020.05.020. Epub 2020 Jun 5.
引用本文的文献
1
Hydroxychloroquine in the treatment of COVID-19: How to use it waiting for conclusive scientific evidence.
Med Clin (Engl Ed). 2020 Aug 14;155(3):134-135. doi: 10.1016/j.medcle.2020.05.003. Epub 2020 Jul 4.
2
[Possible protective factors of SARS-CoV-2 infection in a vulnerable patient: Report of a case].
Semergen. 2020 Aug;46 Suppl 1:95-98. doi: 10.1016/j.semerg.2020.05.013. Epub 2020 Jun 5.
3
Hydroxychloroquine in the treatment of COVID-19: How to use it waiting for conclusive scientific evidence.
Med Clin (Barc). 2020 Aug 14;155(3):134-135. doi: 10.1016/j.medcli.2020.05.006. Epub 2020 May 16.
本文引用的文献
1
[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215-219. doi: 10.3785/j.issn.1008-9292.2020.03.03.
2
Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study.
Travel Med Infect Dis. 2020 Mar-Apr;34:101663. doi: 10.1016/j.tmaid.2020.101663. Epub 2020 Apr 11.
3
Covid-19: six million doses of hydroxychloroquine donated to US despite lack of evidence.
BMJ. 2020 Mar 23;368:m1166. doi: 10.1136/bmj.m1166.
4
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
5
Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine.
Int J Antimicrob Agents. 2020 Apr;55(4):105945. doi: 10.1016/j.ijantimicag.2020.105945. Epub 2020 Mar 17.
6
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
Int J Antimicrob Agents. 2020 May;55(5):105938. doi: 10.1016/j.ijantimicag.2020.105938. Epub 2020 Mar 12.
7
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
8
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Clin Infect Dis. 2020 Jul 28;71(15):732-739. doi: 10.1093/cid/ciaa237.
9
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Int J Antimicrob Agents. 2020 Apr;55(4):105932. doi: 10.1016/j.ijantimicag.2020.105932. Epub 2020 Mar 4.
10
Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools.
Virol Sin. 2020 Jun;35(3):266-271. doi: 10.1007/s12250-020-00207-4. Epub 2020 Mar 3.
Zotero 插件